JP2020505000A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505000A5
JP2020505000A5 JP2019532936A JP2019532936A JP2020505000A5 JP 2020505000 A5 JP2020505000 A5 JP 2020505000A5 JP 2019532936 A JP2019532936 A JP 2019532936A JP 2019532936 A JP2019532936 A JP 2019532936A JP 2020505000 A5 JP2020505000 A5 JP 2020505000A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
protein
acid sequence
target nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505000A (ja
JP7223376B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2016/081077 external-priority patent/WO2018108272A1/en
Application filed filed Critical
Publication of JP2020505000A publication Critical patent/JP2020505000A/ja
Publication of JP2020505000A5 publication Critical patent/JP2020505000A5/ja
Priority to JP2022121297A priority Critical patent/JP2022166045A/ja
Application granted granted Critical
Publication of JP7223376B2 publication Critical patent/JP7223376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532936A 2016-12-14 2017-08-16 熱安定性cas9ヌクレアーゼ Active JP7223376B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022121297A JP2022166045A (ja) 2016-12-14 2022-07-29 熱安定性cas9ヌクレアーゼ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2016/081077 2016-12-14
PCT/EP2016/081077 WO2018108272A1 (en) 2016-12-14 2016-12-14 Thermostable cas9 nucleases
PCT/EP2017/070796 WO2018108338A1 (en) 2016-12-14 2017-08-16 Thermostable cas9 nucleases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022121297A Division JP2022166045A (ja) 2016-12-14 2022-07-29 熱安定性cas9ヌクレアーゼ

Publications (3)

Publication Number Publication Date
JP2020505000A JP2020505000A (ja) 2020-02-20
JP2020505000A5 true JP2020505000A5 (cg-RX-API-DMAC7.html) 2020-09-24
JP7223376B2 JP7223376B2 (ja) 2023-02-16

Family

ID=57755254

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019533096A Active JP7182545B2 (ja) 2016-12-14 2016-12-14 熱安定性cas9ヌクレアーゼ
JP2019533103A Active JP7223377B2 (ja) 2016-12-14 2017-08-16 熱安定性cas9ヌクレアーゼ
JP2019532936A Active JP7223376B2 (ja) 2016-12-14 2017-08-16 熱安定性cas9ヌクレアーゼ
JP2019533098A Active JP7283698B2 (ja) 2016-12-14 2017-12-14 熱安定性cas9ヌクレアーゼ
JP2022121297A Withdrawn JP2022166045A (ja) 2016-12-14 2022-07-29 熱安定性cas9ヌクレアーゼ
JP2022128902A Withdrawn JP2022166170A (ja) 2016-12-14 2022-08-12 熱安定性cas9ヌクレアーゼ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019533096A Active JP7182545B2 (ja) 2016-12-14 2016-12-14 熱安定性cas9ヌクレアーゼ
JP2019533103A Active JP7223377B2 (ja) 2016-12-14 2017-08-16 熱安定性cas9ヌクレアーゼ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019533098A Active JP7283698B2 (ja) 2016-12-14 2017-12-14 熱安定性cas9ヌクレアーゼ
JP2022121297A Withdrawn JP2022166045A (ja) 2016-12-14 2022-07-29 熱安定性cas9ヌクレアーゼ
JP2022128902A Withdrawn JP2022166170A (ja) 2016-12-14 2022-08-12 熱安定性cas9ヌクレアーゼ

Country Status (11)

Country Link
US (5) US11242513B2 (cg-RX-API-DMAC7.html)
EP (4) EP3555275A1 (cg-RX-API-DMAC7.html)
JP (6) JP7182545B2 (cg-RX-API-DMAC7.html)
KR (4) KR20190104342A (cg-RX-API-DMAC7.html)
CN (4) CN110312792B (cg-RX-API-DMAC7.html)
AU (4) AU2016432443B2 (cg-RX-API-DMAC7.html)
BR (3) BR112019012155A2 (cg-RX-API-DMAC7.html)
CA (4) CA3046824A1 (cg-RX-API-DMAC7.html)
EA (4) EA201991443A1 (cg-RX-API-DMAC7.html)
PH (4) PH12019501340A1 (cg-RX-API-DMAC7.html)
WO (3) WO2018108272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
JP7030522B2 (ja) 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法
KR102796744B1 (ko) 2015-06-09 2025-04-15 에디타스 메디신, 인코포레이티드 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
GB201510296D0 (en) * 2015-06-12 2015-07-29 Univ Wageningen Thermostable CAS9 nucleases
US11667911B2 (en) 2015-09-24 2023-06-06 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/CAS-mediated genome editing
SG11201803173VA (en) 2015-10-23 2018-05-30 Harvard College Nucleobase editors and uses thereof
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
CN110312792B (zh) 2016-12-14 2024-04-09 瓦赫宁根大学 热稳定的Cas9核酸酶
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
JP7229923B2 (ja) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド ヌクレアーゼ切断を評価する方法
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
GB201716590D0 (en) * 2017-10-10 2017-11-22 Univ Wageningen Thermostable cas9 nucleases with reduced off-target activity
AU2018352592C1 (en) 2017-10-16 2025-09-25 Beam Therapeutics, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
CN111902536B (zh) * 2018-02-15 2024-07-30 西格马-奥尔德里奇有限责任公司 用于真核基因组修饰的改造的cas9系统
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
JP2022505440A (ja) 2018-11-01 2022-01-14 キージーン ナムローゼ フェンノートシャップ 植物細胞におけるCRISPR/Casゲノム編集のためのデュアルガイドRNA
WO2020099675A1 (en) * 2018-11-16 2020-05-22 Depixus Optimization of in vitro isolation of nucleic acids using site-specific nucleases
RU2712497C1 (ru) * 2018-11-26 2020-01-29 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP2022520104A (ja) 2019-02-15 2022-03-28 シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー Crispr/cas融合タンパク質およびシステム
GB2601617B (en) 2019-03-19 2024-02-21 Broad Inst Inc Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN116694603A (zh) * 2019-05-14 2023-09-05 深圳华大生命科学研究院 新型的Cas蛋白、Crispr-Cas系统及其在基因编辑领域中的用途
US20220348939A1 (en) * 2019-07-30 2022-11-03 Hubei University CRISPR-Cas system for genome editing in Zymomonas mobilis, and applications thereof
CN110331158B (zh) * 2019-07-30 2021-09-14 湖北大学 基于运动发酵单胞菌内源CRISPR-Cas系统的多基因位点同时编辑方法及其应用
CN112410234B (zh) * 2019-08-21 2022-08-23 江南大学 一种多靶点编辑重组曲霉菌株的可视化筛选方法
US11879134B1 (en) * 2019-09-05 2024-01-23 The Regents Of The University Of Colorado, A Body Corporate Recombineering machinery to increase homology directed genome editing in thermophilic microbes
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
CN111778230A (zh) * 2020-07-17 2020-10-16 山东舜丰生物科技有限公司 一种适用于Cas12蛋白的缓冲系统及其应用
RU2749307C1 (ru) * 2020-10-30 2021-06-08 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) Новая компактная нуклеаза CAS9 II типа из Anoxybacillus flavithermus
CN113881652B (zh) * 2020-11-11 2022-11-22 山东舜丰生物科技有限公司 新型Cas酶和系统以及应用
CN114480347B (zh) * 2022-02-21 2022-12-23 中国科学院地球化学研究所 一种纯化Cas12a蛋白的方法
CN114934031B (zh) 2022-05-25 2023-08-01 广州瑞风生物科技有限公司 新型Cas效应蛋白、基因编辑系统及用途
JP7152094B1 (ja) * 2022-06-30 2022-10-12 リージョナルフィッシュ株式会社 tracrRNAユニット、及びゲノム編集方法
CN117701530A (zh) * 2022-12-08 2024-03-15 广州瑞风生物科技有限公司 Cas蛋白截短体、构建其的方法及其应用
CN116144631B (zh) * 2023-01-17 2023-09-15 华中农业大学 耐热型核酸内切酶及其介导的基因编辑系统
WO2025107617A1 (zh) * 2023-11-24 2025-05-30 华智生物技术有限公司 CRISPR/Cas效应蛋白及系统
US20250250641A1 (en) * 2024-02-06 2025-08-07 Florida State University Research Foundation, Inc. Methods and compositions related to epigenetic editing by a methlylation-dependent cas9

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176082B1 (es) 2000-05-31 2004-01-01 Consejo Superior Investigacion Bacterias con la capacidad de unir metales pesados y su empleo en la detoxificacion de medios contaminados con metales pesados.
US7220571B2 (en) 2000-09-28 2007-05-22 Archer-Daniels-Midland Company Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation
US20040101928A1 (en) * 2001-02-23 2004-05-27 Noriko Tsutsumi Lipolytic enzyme genes
US7670807B2 (en) 2004-03-10 2010-03-02 East Tennessee State Univ. Research Foundation RNA-dependent DNA polymerase from Geobacillus stearothermophilus
JP2006230303A (ja) 2005-02-25 2006-09-07 Art Engineering Kk 好熱性リパーゼ産生菌およびその利用
KR100872695B1 (ko) 2006-11-27 2008-12-10 씨제이제일제당 (주) Gras 미생물로부터 발현된 식품안전형 호열성아라비노스 이성화효소 및 그를 이용한 타가토스의제조방법
AU2008210538B2 (en) * 2007-01-31 2013-06-06 Pelican Technology Holdings, Inc. Bacterial leader sequences for increased expression
EP2483400A1 (en) 2009-09-29 2012-08-08 Butamax(tm) Advanced Biofuels LLC Improved flux to acetolactate-derived products in lactic acid bacteria
GB2537000C (en) * 2012-05-25 2019-10-09 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
HRP20220803T1 (hr) 2013-03-15 2022-09-30 Cibus Us Llc Postupci i kompozicije za povećanje efikasnosti modifikacije ciljanog gena korištenjem genske reparacije posredovane oligonukleotidom
FI3116305T3 (fi) 2014-03-14 2024-02-08 Cibus Us Llc Menetelmät ja koostumukset kohdennetun geenimuunnoksen tehokkuuden lisäämiseksi käyttämällä oligonukleotidivälitteistä geeninkorjausta
US10725041B2 (en) 2014-11-04 2020-07-28 Versiti Blood Research Institute Foundation, Inc. Method to bioengineer designer platelets using gene editing and stem cell methodologies
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
BR112017012765A2 (pt) 2014-12-17 2018-01-16 Du Pont ?métodos para editar uma sequência de nucleotídeos, célula e linhagem de e. coli e método para produzir uma célula de e. coli?
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
BR112017024534A2 (pt) * 2015-05-15 2018-07-24 Pioneer Hi Bred Int sistemas de rna-guia/endonuclease cas9 inovadores
GB201510296D0 (en) * 2015-06-12 2015-07-29 Univ Wageningen Thermostable CAS9 nucleases
CN110312792B (zh) 2016-12-14 2024-04-09 瓦赫宁根大学 热稳定的Cas9核酸酶

Similar Documents

Publication Publication Date Title
JP2020505000A5 (cg-RX-API-DMAC7.html)
JP2020510410A5 (cg-RX-API-DMAC7.html)
US11802277B2 (en) Thermostable Cas9 nucleases
US20250230424A1 (en) Modified cascade ribonucleoproteins and uses thereof
JP7223377B2 (ja) 熱安定性cas9ヌクレアーゼ
JP2023002712A (ja) S.ピオゲネスcas9変異遺伝子及びこれによってコードされるポリペプチド
JP6715419B2 (ja) カンピロバクター・ジェジュニcrispr/casシステムに由来するrgenを使用したゲノム編集
JP2019534704A (ja) エピジェネティックに調節される部位特異的ヌクレアーゼ
JP2015503535A5 (cg-RX-API-DMAC7.html)
US20220389418A1 (en) Rna-guided cas nucleases and uses thereof in diagnostics and therapy
US20240247255A1 (en) Methods for modulating cas-effector activity
WO2022210748A1 (ja) 新規なガイドrnaとの複合体形成能を有するポリペプチド
US20250223578A1 (en) Modified cascade ribonucleoproteins and uses thereof
CA2989084C (en) Thermostable cas9 nucleases
HK1231119B (en) Modified cascade ribonucleoproteins and uses thereof
BR112017026719B1 (pt) Complexo de ribonucleoproteína, construto, vetor de expressão, métodos in vitro para modificar um dna ou ácido nucleico alvo, para silenciar a expressão de gene em um locus desejado, para modificar ou deletar e/ou inserir uma sequência de nucleotídeos desejada em um local desejado, e, para detectar e/ou localizar uma mudança de base única em uma molécula de ácido nucleico alvo
HK1231119A1 (en) Modified cascade ribonucleoproteins and uses thereof